90Y Radioembolization for Metastatic Neuroendocrine Liver Tumors

• DOI: 10.1097/sla.0b013e3181728a45
• Publication Date: 2008-05-23T07:06:08Z
• Authors: Thomas K. Rhee; Robert J. Lewando...; David M. Liu; Mary F. Mulcahy; Gary Takahashi; Paul D. Hansen; Al B. Benson; Andrew S. Kennedy; Reed A. Omary; Riad Salem
• Keywords: Glass microsphere

In Brief Purpose: Minimally invasive therapies such as transarterial chemoembolization and radiofrequency ablation are used for hepatic metastatic neuroendocrine tumor (NET) therapy. Results from another minimally therapy, radioembolization, remain unknown. The purpose of this multicenter open label phase II study was to assess the efficacy safety yttrium-90 (90Y) radioembolization treating NET using a primary outcome response secondary outcomes serologic toxicities survival. Material/Methods: study, all patients underwent lobar glass or resin 90Y radioembolic agents. Patients were assessed serologically radiographically at 2 4 weeks then 1 3 month intervals after treatment. We 1) compared liver volumes, radiation doses, function tests (unpaired t test, P = 0.05) 2) response, toxicity, median survival first clinicaltrials.gov identifier NCT00532740. Results: Forty-two (mean age 58 ± 12 years) 61 11 microspheres. A statistically significant greater dose delivered each lobe (right 117 Gy; left 108 Gy) than 50.8 44.5 (P < 0.01). Using Response Criteria in Solid Tumors, 92% 94% classified partial stable disease 6 months Six experienced grade 3/4 during follow-up period. Median 22 (glass) 28 (resin) 0.82). Conclusion: is viable therapy with acceptable toxicity. Further investigation warranted. Transarterial standard care refractory tumors liver. Our objective report on microspheres condition. conclude that represents therapeutic option dominant tumors.